BRANFORD, Conn / Sep 23, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that the Company will host an Investor & Analyst event in New York City on November 19, 2025.
Key members of Quantum-Si’s management team will be present to provide various updates as well as participate in a question and answer session following the formal presentation.
In addition to the in-person live event for invited guests, the event will be live streamed over the internet.
EVENT DETAILS:
WHEN: Wednesday, November 19, 2025 | 10 AM – 12 PM ET
WHERE: Hyatt Centric Times Square, 135 West 45th Street, New York, NY 10036
VIRTUAL ATTENDEE REGISTRATION LINK: Click Here to Register
Investors interested in attending in person should contact QSI investor relations at This email address is being protected from spambots. You need JavaScript enabled to view it.. All others are invited to view the live or archived webcast virtually on the Investor Relations section of Quantum-Si’s website at https://ir.quantum-si.com/.
About Quantum-Si Incorporated
Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.
| Last Trade: | US$2.55 |
| Daily Change: | -0.08 -3.04 |
| Daily Volume: | 48,748,963 |
| Market Cap: | US$465.530M |
September 08, 2025 August 05, 2025 June 17, 2025 June 10, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
